Characterization of β-lapachone and methylated β-cyclodextrin solid-state systems

AAPS PharmSciTech

Volumn 8, Issue 3, 2007, Pages

  Cunha Filho, Marcílio S S ^a   Dacunha Marinho, Bruno ^a   Torres Labandeira, Juan J ^a   Martínez Pancheco, Ramón ^a   Landín, Mariana ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

lapachone; Antitumoral; Crystallinity; Cyclodextrin; Dissolution rate; Inclusion complex

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ANTINEOPLASTIC AGENT; BETA CYCLODEXTRIN; BETA CYCLODEXTRIN DERIVATIVE; BETA CYCLODEXTRIN SULFOBUTYL ETHER; BETA LAPACHONE; 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; BETA-LAPACHONE; CYCLODEXTRIN; NAPHTHOQUINONE; UNCLASSIFIED DRUG;

ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; CRYSTAL; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; DRUG STRUCTURE; FREEZE DRYING; INFRARED SPECTROSCOPY; METHYLATION; MICROSCOPY; SCANNING ELECTRON MICROSCOPY; SOLID STATE; SOLUBILIZATION; X RAY DIFFRACTION; CHEMISTRY; SOLUBILITY;

BETA-CYCLODEXTRINS; CALORIMETRY, DIFFERENTIAL SCANNING; CYCLODEXTRINS; MICROSCOPY, ELECTRON, SCANNING; NAPHTHOQUINONES; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; X-RAY DIFFRACTION;

EID: 34547806076     PISSN: None     EISSN: 15309932     Source Type: Journal    
DOI: 10.1208/pt0803060     Document Type: Article

References (37)

1. Burnett AR, Thomson RH. Naturally occurring quinones. XII: Extractives from Tabebuia chrysantha and other Bignoniaceae. J Chem Soc C. 1968;-:850-853.
2. Hooker SC Jr, Shepard HW Jr, Walsh JG Jr, Connitt GH. Constitution of lapachol and its derivatives. J Am Chem Soc. 1936;58:1190-1197.
3. Guiraud P, Steiman R, Campos-Takaki G, Seigle-Murandi F, Simeon de Buochberg M. Comparison of antibacterial and antifungal activities of lapachol and b-lapachone. Planta Med. 1994;60:373-374.
4. Li CJ, Zhang LJ, Dczube BJ, Crumpacker CS, Pardee AB. Three inhibitors of type 1 human immunodeficiency virus long terminal repeat-directed gene expression and virus replication. Proc Natl Acad Sci USA. 1993;90:1839-1842.
5. Pereira EM, Machado T de B, Leal IC, et al. Tabebuia avellanedae naphthoquinones: Activity against methicillin-resistant staphylococcal strains, cytotoxic activity and in vivo dermal irritability analysis. Ann Clin Microbiol Antimicrob. 2006;5:5.
6. Muller K, Sellmer A, Wiegrebe W. Potential antipsoriatic agents: Lapacho compounds as potent inhibitors of HaCaT cell growth. J Nat Prod. 1999;62:1134-1136.
7. Tudan C, Jackson JK, Higo TT, Burt HM. The effect of inhibiting topoisomerase I and II on the anti-apoptotic response associated with pro-inflammatory crystals of calcium pyrophosphate dihydrate in human neutrophils. Inflamm Res. 2003;52:8-17.
8. Pinto CN, Dantas AP, De Moura KCG, et al. Chemical reactivity studies with naphthoquinones from tabebuia with anti-trypanosoma efficacy. Arzneimittelforschung. 2000;50:1120-1128.
9. Planchon SM, Wuerzberger S, Frydman B, et al. Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: A p53-independent response. Cancer Res. 1995;55:3706-3711.
10. Li Y, Sun X, LaMont JT, Pardee AB, Li CJ. Selective killing of cancer cells by b-lapachone: Direct checkpoint activation as a strategy against cancer. Proc Natl Acad Sci USA. 2003;100:2674-2678.
11. Ough M, Lewis A, Bey EA, et al. Efficacy of beta-lapachone in pancreatic cancer treatment: Exploiting the novel, therapeutic target NQO1. Cancer Biol Ther. 2005;4:95-102.
12. Suzuki M, Amano M, Choi J, et al. Synergistic effects of radiation and beta-lapachone in DU-145 human prostate cancer cells in vitro. Radiat Res. 2006;165:525-531.
13. Jiang Z, Reddy DG, inventors. Pharmaceutical compositions containing b-lapachone or derivatives or analogs. PCT Designated States: Designated States W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT. US patent 7074824. February 13, 2003.
14. Rajews RA, Stella VJ. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J Pharm Sci. 1996;85: 1142-1169.
15. Loftsson T, Brewster ME. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci. 1996;85:1017-1025.
16. Nasongkla N, Wiedmann AF, Bruening A, et al. Enhancement of solubility and bioavailability of beta-lapachone using cyclodextrin inclusion complexes. Pharm Res. 2003;20:1626-1633.
17. Wang F, Blanco E, Ai H, Boothman DA, Gao J. Modulating beta-lapachone release from polymer millirods through cyclodextrin complexation. J Pharm Sci. 2006;95:2309-2319.
18. Cao F, Guo J, Ping Q. The physicochemical characteristics of freeze-dried scutellarin-cyclodextrin tetracomponent complexes. Drug Dev Ind Pharm. 2005;31:747-756.
19. Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: Past, present and future. Nat Rev Drug Discov. 2004;3:1023-1035.
20. Soares da Cunha Filho MS, Alves FC, Alves GMC, Monteiro DB, Morais de Medeiros FP, Rolim Neto PJ. Beta-lapachone: Development and validation of analytical method for the new therapeutic antineoplastic alternative. Rev Bras Farm. 2005;86:39-43.
21. Higuchi T, Connors KA. Phase solubility techniques. Adv Anal Chem. 1965;4:117-212.
22. Hedges AR. Industrial applications of cyclodextrins. Chem Rev. 1998;98:2035-2044.
23. Balzar D, Audebrand N, Daymond MR, et al. Size-strain line-broadening analysis of the ceria round-robin sample. Appl Cryst. 2004;37:911-924.
24. Warren BE, Averbach BL. The effect of cold work in metals on powder pattern intensities. J Appl Phys. 1949;20:1066-1069.
25. Roisnel T, Rodriguez-Carvajal J. WinPLOTR: A Windows tool for powder diffraction patterns analysis Materials Science. Proceedings of European Powder Diffraction Conference; May 20-23, 2000; Barcelona, Spain. Stafa-Zurich, Switzerland: Trans Tech Publications; 2000:118-123.
26. Cline JP, Deslattes RD, Staudenmann JL. Certificate SRM 660a. Gaithersburg, MD: NIST; 2000.
27. Veiga MD, Diaz PJ, Ahsan F. Interactions of griseofulvin with cyclodextrins in solid binary systems. J Pharm Sci. 1998;87:891-900.
28. US Department of Health and Human Services. Guidance for Industry: Dissolution Testing of Immediate Release Solid Oral Dosage Forms, August 1997. Available at: http://www.fda.gov/cder/guidance/1713bp1.pdf. Accessed January 23, 2007.
29. Khan KA, Rhodes CT. Effect of compaction pressure on the dissolution efficiency of some direct compression systems. Pharm Acta Helv. 1972;47:594-607.
30. Fernández-Palacín F, López Sánchez MA, Muñoz Márquez MA, Rodríguez-Chía M, Sánchez-Navas A, Valero-Franco C. Estadística Asistida por Ordenador Statgraphics Plus 4.1. Cádiz: Universidad de Cádiz; 2000.
31. Mura P, Furlanetto S, Cirri M, Maestrelli F, Corti G, Pinzauti S. Interaction of naproxen with ionic cyclodextrins in aqueous solution and in the solid state. J Pharm Biomed Anal. 2005;37:987-994.
32. Jacquet R, Elfakir C, Lafosse M. Characterization of a new methylated beta-cyclodextrin with a low degree of substitution by electrospray ionization mass spectrometry and liquid chromatography/mass spectrometry. Rapid Commun Mass Spectrom. 2005;19:3097-3102.
33. Cunha-Filho MS, Landin M, Martinez-Pacheco R, Dacunha-Marinho B. Beta-lapachone. Acta Crystallogr C. 2006;62:o473-o475.
34. Frooming K, Szejtli J. Cyclodextrin in Pharmacy. London, UK: Kluwer Academic Publishers; 1994.
35. Cabral Marques HM, Hadgraft J, Kellaway IW. Studies of cyclodextrin inclusion complexes. I. The salbutamol-cyclodextrin complex as studied by phase solubility and DSC. Int J Pharm. 1990;63:259-266.
36. Cirri M, Rangoni C, Maestrelli F, Corti G, Mura P. Development of fast-dissolving tablets of flurbiprofen-cyclodextrin complexes. Drug Dev Ind Pharm. 2005;31:697-707.
37. Fernandes CM, Teresa Vieira M, Veiga FJB. Physicochemical characterization and in vitro dissolution behavior of nicardipine-cyclodextrins inclusion compounds. Eur J Pharm Sci. 2002; 15:79-88.